Le Lézard
Classified in: Health
Subjects: CCA, SLS

Capio to Publish Interim Report on October 27, 2017


GOTHENBURG, Sweden, Oct. 6, 2017 /PRNewswire/ -- Capio AB will publish the interim report for January-September 2017 on Friday, October 27 at approximately 08.00 am (CET).

08.00 am (approximately)

Report release. The report will be sent as a press release and will be published on Capio's website www.capio.com.

09.30 am Telephone conference and audio cast

Investors, analysts and media are invited to participate in a telephone conference at 09.30 am (CET).

President and CEO Thomas Berglund and CFO Olof Bengtsson will present the report and answer questions (in English).

The telephone conference will be audio casted live on www.capio.com.

To participate in the telephone conference, please register at www.capio.com and dial in five minutes prior to the start of the conference call.

Sweden: +46-8-566-426-93 UK: +44-203-008-98-04 US: +1-855-753-22-37 Finland: +35-898-171-04-93 France: +33-170-75-07-12

Prior to the start of the telephone conference, presentation slides will be available at www.capio.com.

A recorded version of the audio cast will be made available at

www.capio.com

during the afternoon (CET).

Subscribe to press releases and financial information

To receive press releases and financial reports from Capio, please subscribe at www.capio.com/subscribe.

For information, please contact:
Olof Bengtsson
CFO
Telephone: +46-761-18-74-69

Kristina Ekeblad
IR manager
Telephone: +46-708-31-19-40

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/capio-ab/r/capio-to-publish-interim-report-on-october-27--2017,c2361694

The following files are available for download:

http://mb.cision.com/Main/277/2361694/732442.pdf

PDF


These press releases may also interest you

at 07:00
Bristol Myers Squibb today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo® (nivolumab) in combination with cisplatin and gemcitabine for the...

at 06:50
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...



News published on and distributed by: